TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35249859

Group type: EXPERIMENTAL
Intervention: Exercise intervention (30 exercise sessions within four months)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group (completed measures only)
Number of subjects: 800
Study: 32565092

Group type: EXPERIMENTAL
Intervention: Transitional care program (ongoing rehabilitation at specialized care center and home)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Routine follow‐up visits by primary healthcare physicians (control)
Number of subjects: 84
Study: 32487120

Group type: EXPERIMENTAL
Intervention: Happiness Route (positive psychology intervention)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control condition (traditional problem-based approach)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Happiness Route
Number of subjects: 108
Study: 36047035

Group type: EXPERIMENTAL
Intervention: Cognitive training & exercise (CT&E)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Cognitive training (CT)
Number of subjects: 47
Study: 33908691

Group type: EXPERIMENTAL
Intervention: Combined exenatide-dapagliflozin
Number of subjects: 66

Group type: COMPARATOR
Intervention: Dapagliflozin
Number of subjects: 66

Group type: COMPARATOR
Intervention: Exenatide
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 32195729

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no additional treatment)
Number of subjects: 8
Study: 35749371

Group type: EXPERIMENTAL
Intervention: Antenatal diet and lifestyle intervention
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Maternal early pregnancy BMI
Number of subjects: 645
Study: 33975465

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (fluoropyrimidine and platinum-based agent)
Number of subjects: 1542

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (fluoropyrimidine and platinum-based agent)
Number of subjects: 1542
Study: 33392137

Group type: EXPERIMENTAL
Intervention: Climate change affected scenario (CCA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Climate change unaffected scenario (CCU)
Number of subjects: 0
Study: 35777110

Group type: EXPERIMENTAL
Intervention: Moderately high protein (MHP) diet
Number of subjects: 190

Group type: COMPARATOR
Intervention: Low fat (LF) diet
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Model including genetic information
Number of subjects: 190
Study: 34463929

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (target serum level 3 mg/dl)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Normal saline (placebo, target serum level 1.9 mg/dl)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 72

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate and normal saline (placebo)
Number of subjects: 72
Study: 36181292

Group type: EXPERIMENTAL
Intervention: 308nm excimer laser
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus
Number of subjects: 21

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 21
Study: 33108981

Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC) intervention
Number of subjects: 161
Study: 33245004

Group type: EXPERIMENTAL
Intervention: PCV7
Number of subjects: 350

Group type: COMPARATOR
Intervention: PHiD-CV
Number of subjects: 350
Study: 36277954

Group type: EXPERIMENTAL
Intervention: Moringa oleifera Lam. leaf supplementation (MOG)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (COG)
Number of subjects: 200
Study: 33003575

Group type: EXPERIMENTAL
Intervention: Elastic Band Exercise (EBE) for 60 min, three times a week for 12 weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Elastic Band Exercise (EBE)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 27
Study: 34861772

Group type: EXPERIMENTAL
Intervention: Thyroid Lobectomy (TL)
Number of subjects: 918

Group type: COMPARATOR
Intervention: Total Thyroidectomy (TT)
Number of subjects: 918
Study: 34929497

Group type: EXPERIMENTAL
Intervention: Optimized intraoperative infection control program
Number of subjects: 801
Study: 32767582

Group type: EXPERIMENTAL
Intervention: LF GA
Number of subjects: 15

Group type: COMPARATOR
Intervention: HF GA
Number of subjects: 15

Group type: COMPARATOR
Intervention: LF St
Number of subjects: 15
Study: 32209071

Group type: EXPERIMENTAL
Intervention: Youth-friendly sexual and reproductive health services
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Input quality (availability of trained providers, drugs, and supplies)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Process component (client-provider interaction and privacy/confidentiality)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Community-based health insurance and age-driven comprehensive youth-friendly service delivery approach
Number of subjects: 54
Study: 35247831

Group type: EXPERIMENTAL
Intervention: Workstation adjustments (EG)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 61
Study: 34649217

Group type: EXPERIMENTAL
Intervention: 400 mg/day ALA
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 800 mg/day ALA
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 34972663

Group type: EXPERIMENTAL
Intervention: Duodenal tumors
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Jejunal tumors
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Ileal tumors
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Duodenal tumors (metastatic disease)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Jejunal tumors (metastatic disease)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Ileal tumors (metastatic disease)
Number of subjects: 340
Study: 34639518

Group type: EXPERIMENTAL
Intervention: Teleconsultation for diabetes mellitus
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Regula Mais Brasil Collaborative project
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Brasil Redes project
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: TELEconsulta Diabetes (randomized clinical trial)
Number of subjects: 161
Study: 35718935

Group type: EXPERIMENTAL
Intervention: Ultra-pure soft water (UPSW)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Tap water (TW)
Number of subjects: 43
Study: 34473896

Group type: EXPERIMENTAL
Intervention: Polypropylene mesh inlay
Number of subjects: 2632

Group type: EXPERIMENTAL
Intervention: Polypropylene mesh kit
Number of subjects: 2632

Group type: EXPERIMENTAL
Intervention: Biological xenograft
Number of subjects: 2632

Group type: EXPERIMENTAL
Intervention: Native tissue
Number of subjects: 2632

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 2632
Study: 36414304

Group type: EXPERIMENTAL
Intervention: Leucocyte-poor platelet-rich plasma (PRP) injection after joint aspiration
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo control group receiving only joint aspiration
Number of subjects: 80
Study: 35473371

Group type: EXPERIMENTAL
Intervention: Surgical mask
Number of subjects: 28

Group type: COMPARATOR
Intervention: No mask (control)
Number of subjects: 28
Study: 34559359

Group type: EXPERIMENTAL
Intervention: Ciprofol initial infusion for 30 min followed by continuous maintenance infusion for 4 hours
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ciprofol bolus dose followed by continuous maintenance infusion for 12 hours
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ciprofol and propofol pharmacokinetic parameters
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ciprofol and propofol pharmacodynamic parameters
Number of subjects: 16
Study: 35066398

Group type: EXPERIMENTAL
Intervention: Exergame training
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Video game training
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study: 33622392

Group type: EXPERIMENTAL
Intervention: Modified ketogenic diet
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual diet supplemented with low-fat healthy-eating guidelines
Number of subjects: 26
Study: 32186108

Group type: EXPERIMENTAL
Intervention: Hand-ear acupuncture
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard acupuncture
Number of subjects: 152

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 152
Study: 36644351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: SCO-792 500 mg once daily (SCO-792 QD)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: SCO-792 500 mg 3 times daily (SCO-792 TID)
Number of subjects: 72
Study: 34345921

Group type: EXPERIMENTAL
Intervention: Educational outreach intervention
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Redesigned discharge instructions template
Number of subjects: 225

Group type: COMPARATOR
Intervention: Baseline readmission rate
Number of subjects: 225

Group type: COMPARATOR
Intervention: After educational outreach
Number of subjects: 225

Group type: COMPARATOR
Intervention: After redesigned template
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Medical students
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Residents
Number of subjects: 225
Study: 32476465

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0
Study: 34184620

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Stress Management (SM)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 52
Study: 35078832

Group type: EXPERIMENTAL
Intervention: Preventive Antenatal Educational Program on Allergic Diseases (PAEPAD)
Number of subjects: 2266

Group type: COMPARATOR
Intervention: Standard neonatal care education
Number of subjects: 2266
Study: 33124789

Group type: EXPERIMENTAL
Intervention: Core training (30‐35 min, three days a week for eight weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Routine training (control group)
Number of subjects: 24
Study: 35596945

Group type: EXPERIMENTAL
Intervention: Mbereko+Men intervention
Number of subjects: 457

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 457
Study: 33222542

Group type: EXPERIMENTAL
Intervention: Selective internal radiation therapy (SIRT) with Y-90 resin microspheres
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 0
Study: 36494706

Group type: EXPERIMENTAL
Intervention: Cardiac shockwave therapy (SWT) during CABG surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: CABG surgery with sham treatment
Number of subjects: 80
Study: 32342235

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 35780574

Group type: EXPERIMENTAL
Intervention: HD-tDCS (1, 2, and 3 mA)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 11
Study: 32964809

Group type: EXPERIMENTAL
Intervention: PAI-indicated treatment in STEPd study
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: PAI-indicated treatment in FreqMech study
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Cross-trial predictions for indicated treatment
Number of subjects: 351
Study: 32557665

Group type: EXPERIMENTAL
Intervention: Intravenous garetosmab 0.3, 1, 3, or 10 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous garetosmab 10 mg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 36163755

Group type: EXPERIMENTAL
Intervention: Quizartinib (40 mg/day from days 8-21, followed by 30-60 mg/day for up to 3 years)
Number of subjects: 539

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Quizartinib
Number of subjects: 539
Study: 34336162

Group type: EXPERIMENTAL
Intervention: Artificial intelligence image group using hybrid segmentation network (HSN) model for analyzing brain images.
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group using original images for diagnosis and treatment.
Number of subjects: 73
Study: 35818232

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 regimen combined with SHR‐1210
Number of subjects: 60

Group type: COMPARATOR
Intervention: mFOLFOX6 regimen
Number of subjects: 60
Study: 34373901

Group type: EXPERIMENTAL
Intervention: Active motor cortex stimulation ('on')
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham motor cortex stimulation ('off')
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Postoperative analgesic effect after electrode insertion
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Motor cortex stimulation
Number of subjects: 18
Study: 32374710

Group type: EXPERIMENTAL
Intervention: Communication skills training for oncologists (2-hour training and four coaching sessions)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Usual care for oncologists
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Communication skills training (INT)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: INT group
Number of subjects: 265

Group type: COMPARATOR
Intervention: UC group
Number of subjects: 265
Study: 35276977

Group type: EXPERIMENTAL
Intervention: Group SS (ONS up to 14 days preoperatively and postoperatively up to discharge)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Group SS-E (ONS up to 14 days preoperatively, postoperatively up to discharge and for an extended 90‐days after discharge)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Group DS (ONS postoperatively up to discharge)
Number of subjects: 91
Study: 32687174

Group type: EXPERIMENTAL
Intervention: Naphthoquine-Azithromycin (NQAZ)
Number of subjects: 631

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 631
Study: 33676783

Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine (three-dose regimen: day 1, month 2, month 6)
Number of subjects: 1212
Study: 32914890

Group type: EXPERIMENTAL
Intervention: 15 SNPs from three different loci (8p11.22, 8p12, 3q25.31)
Number of subjects: 4531

Group type: EXPERIMENTAL
Intervention: 12 SNPs from 3q25.31 locus
Number of subjects: 4531
Study: 34791836

Group type: EXPERIMENTAL
Intervention: Ibrutinib monotherapy
Number of subjects: 88
Study: 32954673

Group type: EXPERIMENTAL
Intervention: Repetitive movements
Number of subjects: 39

Group type: COMPARATOR
Intervention: Biological movements
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Visual preference patterns
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Heterogeneity of visual preferences
Number of subjects: 39
Study: 34617663

Group type: EXPERIMENTAL
Intervention: 5% potassium nitrate dentifrice
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo dentifrice without KNO3
Number of subjects: 38
Study: 32921364

Group type: EXPERIMENTAL
Intervention: Fish oil containing lipid emulsion (Lipidem® 20%, BBraun) for 7 days
Number of subjects: 45

Group type: COMPARATOR
Intervention: Lipid emulsion without fish oil (Lipofundin® MCT 20%, BBraun)
Number of subjects: 45
Study: 36286605

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg
Number of subjects: 885

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 885
Study: 34134711

Group type: EXPERIMENTAL
Intervention: Low serum urate (100 µmol/L)
Number of subjects: 359192

Group type: EXPERIMENTAL
Intervention: Median serum urate (300 µmol/L)
Number of subjects: 359192
Study: 32073940

Group type: EXPERIMENTAL
Intervention: Low-risk pragmatic randomized controlled trials (pRCTs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: EU clinical trial regulation
Number of subjects: 0
Study: 34923848

Group type: EXPERIMENTAL
Intervention: Continuous tafamidis (meglumine 80 mg)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Placebo to tafamidis
Number of subjects: 353
Study: 33568796

Group type: EXPERIMENTAL
Intervention: Topiramate (200 mg daily for 12 weeks)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 170
Study: 32353974

Group type: EXPERIMENTAL
Intervention: Gymnema sylvestre (GS) solution
Number of subjects: 15

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 15
Study: 36039531

Group type: EXPERIMENTAL
Intervention: Combined training (two resistance sessions and one endurance session per week for 8 weeks)
Number of subjects: 40
Study: 33611742

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 50 mg/kg intravenously, followed by infusion at a rate of 10 mg/kg/h during surgery
Number of subjects: 52

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 52
Study: 35379403

Group type: EXPERIMENTAL
Intervention: Mobile tele-counseling
Number of subjects: 162

Group type: COMPARATOR
Intervention: Brief advice
Number of subjects: 162
Study: 33162191

Group type: EXPERIMENTAL
Intervention: Patient education program topics as identified by patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: Patient education program topics as identified by caregivers
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Common topics identified by both patients and caregivers
Number of subjects: 38
Study: 35467968

Group type: EXPERIMENTAL
Intervention: 3D simulator
Number of subjects: 32

Group type: COMPARATOR
Intervention: 2D simulator
Number of subjects: 32
Study: 32096321

Group type: EXPERIMENTAL
Intervention: Participants with a history of any respiratory disease or those living in rural/remote communities
Number of subjects: 1278

Group type: EXPERIMENTAL
Intervention: Entire cohort
Number of subjects: 1278

Group type: COMPARATOR
Intervention: ‘Healthy’ group
Number of subjects: 1278

Group type: EXPERIMENTAL
Intervention: ‘Respiratory history’ group
Number of subjects: 1278
Study: 34035112

Group type: EXPERIMENTAL
Intervention: DMSO
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: DMSO + imiquimod
Number of subjects: 28

Group type: COMPARATOR
Intervention: IFA
Number of subjects: 28

Group type: COMPARATOR
Intervention: IFA + imiquimod
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Group 4 (DMSO + imiquimod)
Number of subjects: 28
Study: 34988991

Group type: EXPERIMENTAL
Intervention: Family Formation (FF)
Number of subjects: 692

Group type: COMPARATOR
Intervention: Economic Stability (ES)
Number of subjects: 692
Study: 33743112

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 493

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study: 32546148

Group type: EXPERIMENTAL
Intervention: Assertive case management
Number of subjects: 914

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 914
Study: 34788466

Group type: EXPERIMENTAL
Intervention: On-pump coronary artery bypass graft surgery
Number of subjects: 4752

Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass graft surgery
Number of subjects: 4752
Study: 32871238

Group type: EXPERIMENTAL
Intervention: Calcifediol treatment (0.532 mg on admission, 0.266 mg on days 3 and 7, then weekly until discharge or ICU admission)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Best available therapy (hydroxychloroquine and azithromycin) without calcifediol
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Calcifediol treatment
Number of subjects: 76

Group type: COMPARATOR
Intervention: Best available therapy without calcifediol
Number of subjects: 76
Study: 35854329

Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo acupuncture (non-penetrating)
Number of subjects: 198
Study: 34211099

Group type: EXPERIMENTAL
Intervention: High-dose BTxA (8 U)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low-dose BTxA (4 U)
Number of subjects: 22
Study: 32880343

Group type: EXPERIMENTAL
Intervention: PZQ 40 mg/kg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: PZQ 60 mg/kg
Number of subjects: 79
Study: 33190274

Group type: EXPERIMENTAL
Intervention: Warning message for severe weather
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Warning message for act of violence
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Warning message for breakdown of emergency number
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Warning message for discovery of a World War II bomb
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Warning message for major fire
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Warning message
Number of subjects: 614
Study: 32171600

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of botulinum toxin A (BTX‐A) in the masticator muscles before surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline injections (Control)
Number of subjects: 20
Study: 33720882

Group type: EXPERIMENTAL
Intervention: CCT alone (group-based CCT 3x/week for 1 hour plus 3x/week home-based training)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: CCT with brisk walking (Ex+CCT)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (group‐based balanced and toned (BAT) classes 3x/week for 1 hour)
Number of subjects: 124
Study: 32783644

Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg (SPARTAN only)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34569413

Group type: EXPERIMENTAL
Intervention: Lubricant gel (5 ml of water-soluble lubricant gel during cervical dilatation of 4 cm until complete cervical dilatation)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 110
Study: 32072592

Group type: EXPERIMENTAL
Intervention: Treatment group (specific intervention not detailed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Augmented control group (external data used)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 0
Study: 35986409

Group type: EXPERIMENTAL
Intervention: Oral glucose intake
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo intake
Number of subjects: 108
Study: 33782121

Group type: EXPERIMENTAL
Intervention: Empathic supervision intervention with probation or parole officers (PPOs)
Number of subjects: 20478
Study: 32473640

Group type: EXPERIMENTAL
Intervention: OM3-CA 2 g
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: OM3-CA 4 g
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: OM3-EE 4 g
Number of subjects: 15